5-Methyl-2-pyrrolidone → 1-{5-[4-(5-Cyclopropyl-3-methylpyridin-2-yl)piperazine-1-carbonyl]-6-methylpyridin-2-yl}-5-methylpyrrolidin-2-one
반응식
Br[C:2]1[N:7]=[C:6]([CH3:8])[C:5]([C:9]([N:11]2[CH2:16][CH2:15][N:14]([C:17]3[C:22]([CH3:23])=[CH:21][C:20]([CH:24]4[CH2:26][CH2:25]4)=[CH:19][N:18]=3)[CH2:13][CH2:12]2)=[O:10])=[CH:4][CH:3]=1.[CH3:27][CH:28]1[NH:32][C:31](=[O:33])[CH2:30][CH2:29]1>>[CH:24]1([C:20]2[CH:21]=[C:22]([CH3:23])[C:17]([N:14]3[CH2:15][CH2:16][N:11]([C:9]([C:5]4[CH:4]=[CH:3][C:2]([N:32]5[CH:28]([CH3:27])[CH2:29][CH2:30][C:31]5=[O:33])=[N:7][C:6]=4[CH3:8])=[O:10])[CH2:12][CH2:13]3)=[N:18][CH:19]=2)[CH2:26][CH2:25]1참가 물질
3
실험 절차
Using (6-bromo-2-methylpyridin-3-yl)[4-(5-cyclopropyl-3-methylpyridin-2-yl)piperazin-1-yl]methanone (150 mg) described in Preparation Example 249 and 5-methylpyrrolidin-2-one (54 mg) and by the reaction and treatment in the same manner as in Example 262, the title compound (138 mg) was obtained.